Showing 4206 results for "als"

Filter By

In trial, Neuronata-R benefits ALS patients with slower progression

In adults with amyotrophic lateral sclerosis (ALS) who have slower disease progression, the stem cell therapy Neuronata-R (lenzumestrocel) — conditionally approved in South Korea for treating ALS — was found to help preserve daily function and breathing capacity, while also reducing signs of nerve damage and inflammation. That’s according to…

Setting an intention each day is part of my ALS tool kit

Come on, do we really need another reminder to practice self-care? I think we do. I know I need it, especially because I have ALS and am living in a world that’s barreling down a bumpy track. The type of self-care I’m currently focusing on isn’t a self-indulgent three-day vacation,…

New study IDs better method to detect gene defects in sporadic ALS

Long-read DNA sequencing is a more accurate method than short-read sequencing for detecting certain defects in genes associated with an increased risk of sporadic amyotrophic lateral sclerosis (ALS), a new study suggests. A relatively new technique, long-read sequencing can capture data on thousands to hundreds of thousands of nucleotides,…

New study may explain why ALS therapy BIIB078 didn’t work

The investigational antisense oligonucleotide (ASO) therapy BIIB078 may have failed in amyotrophic lateral sclerosis (ALS) clinical trials because it wasn’t adequately reversing key disease processes in the brain and spinal cord. Analyses of body fluids and tissue from participants showed that, while BIIB078 reached key tissues, it couldn’t entirely…

While living with ALS, panic leads to stress again and again

A friend who stopped by for a visit last weekend asked my husband, Todd, “Anything new?” “Not really,” he said. “So no more choking incidents?” she asked. “There have been choking incidents, and Kristin has to clear my lungs every couple days,” he replied, “but you asked if there was…

AP-101 holds promise for some with ALS, topline data show

AP-101, AL-S Pharma’s amyotrophic lateral sclerosis (ALS) therapy, was safe and well tolerated and led to clinically meaningful benefits for breathing and survival after one year of treatment. That’s according to topline data from a now-complete Phase 2a study (NCT05039099) that tested the therapy in 73 adults with…